Statera License Agreement - Summary of Milestone Payments and Milestone Payment Obligations (Details) - License Agreement - USD ($)		3 Months Ended
	Feb. 11, 2025	Mar. 31, 2025
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments	$ 1,750,000	$ 500,000
Milestone payment obligations	6,500,000
Validation of current inventory of Materials for distribution and sales
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments	750,000
Filing of BLA with FDA for Acute Radiation Syndrome
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments	1,000,000
File IND and Initiate Phase 2 Clinical Study for Neutropenia
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment obligations	500,000
Phase III Completion - successfully meets endpoint required to secure FDA approval for treatment of Neutropenia
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment obligations	750,000
File BLA with FDA and achieve FDA Approval for Neutropenia
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment obligations	1,500,000
File IND and Initiate Phase 2 study of Lymphocyte Exhaustion
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment obligations	500,000
Phase III Completion - successfully meets endpoint required by FDA for treatment of Lymphocye Exhaustion
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment obligations	750,000
File BLA with FDA and achieve FDA Approval for Lymphocyte Exhaustion
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment obligations	1,500,000
IND approval and initiation of Phase 3 study as a Vaccine Adjuvant
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment obligations	500,000
File US BLA with FDA and achieve FDA Approval for use as a Vaccine Adjuvant
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment obligations	$ 500,000